Clopidogrel Tablet
Product Images NDC 33342-060

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Clopidogrel (NDC 33342-060). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Macleods Pharmaceuticals Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Clopidogrel-100s (Clopidogrel 100s)

Clopidogrel Tablets, USP 75 mg oral tablets packaging label from Macleods Pharmaceuticals Limited. The label includes the product name and strength, NDC 33342-060-12, pharmacist dispensing instructions, quantity of 100 tablets (10 x 10 unit dose), batch and expiration date fields, manufacturer information, and storage instructions.*

FDA Label Image

Clopidogrel-30s (Clopidogrel 30s)

Clopidogrel Tablets USP 75 mg tablet label from Macleods Pharmaceuticals Limited. The label includes the drug strength, NDC 33342-060-07, pharmacist dispensing instructions, storage conditions (20° to 25°C), batch and expiration date area, and manufacturing information for Macleods Pharma USA and Macleods Pharmaceuticals Ltd, India. Package contains 30 tablets.*

FDA Label Image

Clopidogrel-500s (Clopidogrel 500s)

Clopidogrel Tablets, USP 75 mg oral tablets label from Macleods Pharmaceuticals Limited. The label shows the product strength as 75 mg per tablet and package count of 500 tablets. It is manufactured for Macleods Pharma USA, Inc., Plainsboro, NJ, and manufactured by Macleods Pharmaceuticals Ltd., Baddi, Himachal Pradesh, India. Storage instructions and pharmacist dispensing guidance are also present on the label.*

FDA Label Image

Clopidogrel-90s (Clopidogrel 90s)

Clopidogrel Tablets, USP 75 mg oral tablets label by Macleods Pharmaceuticals Limited. The label states 90 tablets per package and includes storage instructions (20° to 25°C, with permitted excursions), active ingredient content (97.875 mg clopidogrel bisulfate equivalent to 75 mg clopidogrel base), manufacturer details, and instructions for pharmacist dispensing a Medication Guide.*

FDA Label Image

Figure-03 (Clopidogrel Fig 3)

A forest plot comparing the hazard ratios and 95% confidence intervals for Clopidogrel versus placebo across various patient subgroups defined by heparin/LMWH use, aspirin dosage, GPIIb/IIIa antagonist use, beta-blocker use, and ACE inhibitor use. The overall comparison is also shown, with hazard ratios plotted along a horizontal axis ranging from 0.3 to 1.4.*

FDA Label Image

Figure-1 (Clopidogrel Figure 01)

A forest plot chart showing the effect of co-administered proton pump inhibitors (PPIs) Dexlansoprazole 60 mg, Lansoprazole 30 mg, Pantoprazole 80 mg, and Omeprazole 80 mg on the active metabolite area under the curve (AUC) relative to clopidogrel administered alone. The x-axis represents change relative to clopidogrel alone, with values ranging approximately from 0.4 to 1.4, and horizontal lines indicate mean and 90% confidence intervals for each PPI.*

FDA Label Image

Figure-2 (Clopidogrel Figure 02)

A line chart depicting cumulative event rates of cardiovascular death, myocardial infarction, and stroke over 12 months of follow-up. Two groups are compared: one receiving placebo plus aspirin and the other clopidogrel plus aspirin. The clopidogrel group shows a lower cumulative event rate throughout the period, with a statistical significance indicated by P=0.00009.*

FDA Label Image

Figure-4 (Clopidogrel Figure 04)

A Kaplan-Meier survival curve depicting percentage of deaths before first discharge over 28 days among two groups: one receiving placebo and the other receiving clopidogrel. The graph shows slightly fewer deaths in the clopidogrel group (7.5%) compared to placebo (8.1%), with a 7% proportional risk reduction (p = 0.03). The x-axis represents days since randomization, and the y-axis represents percentage dead before discharge.*

FDA Label Image

Figure-5 (Clopidogrel Figure 05)

A Kaplan-Meier survival curve chart comparing the percentage of patients with death, reinfarction, or stroke before first discharge over 28 days between Clopidogrel and placebo groups. The vertical axis shows the percentage with events, and the horizontal axis shows days since randomization, up to 28 days. Clopidogrel shows a lower event rate compared to placebo, with a noted 9% proportional risk reduction (p = 0.002).*

FDA Label Image

Fig-7 (Clopidogrel Figure 07)

A line graph depicting the cumulative event rate percentage of fatal or non-fatal vascular events over 36 months of follow-up for Clopidogrel and Aspirin. The cumulative event rate increases over time for both drugs, with Aspirin showing a slightly higher rate than Clopidogrel. Statistical significance is indicated with a P value of 0.045.*

FDA Label Image

Figure-3 (Clopidogrel Figure 3)

A data table showing subgroup analysis comparing Clopidogrel versus placebo outcomes. It includes subgroups by age, gender, race, elevated cardiac enzymes, diabetes, previous myocardial infarction (MI), and previous stroke. The table presents patient counts, event percentages, and hazard ratios with confidence intervals graphically depicting favorability toward Clopidogrel or placebo.*

FDA Label Image

Figure-6 (Clopidogrel Figure 6)

A forest plot chart depicting odds ratios with 99% confidence intervals comparing Clopidogrel versus placebo across various subgroups defined by gender, age at entry, hours since onset, systolic blood pressure, heart rate, and fibrinolytic agent use. The plot visually represents whether data favors Clopidogrel or placebo for each subgroup and includes sample sizes (N) and event counts for both Clopidogrel and placebo groups.*

FDA Label Image

Figure-8 (Clopidogrel Figure 8)

A forest plot chart depicting hazard ratios (with 95% confidence intervals) comparing the effectiveness of Clopidogrel versus Aspirin across qualifying conditions including Stroke, Myocardial Infarction (MI), Peripheral Arterial Disease (PAD), and Overall. The horizontal axis shows hazard ratios ranging from 0.6 to 1.3, with markers indicating relative favorability for Clopidogrel or Aspirin.*

FDA Label Image

Structure (Clopidogrel Structure)

Chemical structure of Clopidogrel, showing its molecular configuration including a thiophene ring, chlorophenyl group, and methyl ester functional groups, with an associated sulfuric acid molecule.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.